Reconsidering clindamycin-rifampicin use in hidradenitis suppurativa: balancing anti-inflammatory benefits and resistance risk

dc.contributor.authorAltunisik Toplu, Sibel
dc.contributor.authorAltunisik, Nihal
dc.date.accessioned2026-04-04T13:33:31Z
dc.date.available2026-04-04T13:33:31Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstract[No abstract available]
dc.identifier.doi10.1093/ced/llaf357
dc.identifier.endpage2505
dc.identifier.issn0307-6938
dc.identifier.issn1365-2230
dc.identifier.issue12
dc.identifier.orcid0000-0002-2915-4666
dc.identifier.pmid40737519
dc.identifier.scopus2-s2.0-105022816328
dc.identifier.scopusqualityQ2
dc.identifier.startpage2505
dc.identifier.urihttps://doi.org/10.1093/ced/llaf357
dc.identifier.urihttps://hdl.handle.net/11616/109198
dc.identifier.volume50
dc.identifier.wosWOS:001562524300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.ispartofClinical and Experimental Dermatology
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.titleReconsidering clindamycin-rifampicin use in hidradenitis suppurativa: balancing anti-inflammatory benefits and resistance risk
dc.typeLetter

Dosyalar